Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, Cytokinetics, Incorporated reported revenue of $88M, up 376.6% year over year. Operating margin was -695.4% and net margin -891.6%, on a free-cash-flow margin of -607.5% with capital expenditure at 28.2% of revenue. Every figure is computed directly from CYTK's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $88M | -695.4% | -891.6% |
| FY2024 | $18M | -2902.7% | -3191.1% |
| FY2023 | $8M | -6589.7% | -6988.6% |
| FY2022 | $95M | -342.8% | -411.2% |
| FY2021 | $70M | -264.5% | -305.7% |
How does CYTK compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: AAWH · ABBV · ABCL · ABT · ABUS · ACAD
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.